As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.
7 Analysts have issued a Pulse Biosciences, Inc. forecast:
7 Analysts have issued a Pulse Biosciences, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 0.09 0.09 |
-
|
|
| Gross Profit | -0.19 -0.19 |
-
|
|
| EBITDA | -78 -78 |
64%
64%
|
|
| EBIT (Operating Income) EBIT | -79 -79 |
63%
63%
|
|
| Net Profit | -75 -75 |
62%
62%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
| Head office | United States |
| CEO | Paul LaViolette |
| Employees | 75 |
| Founded | 2014 |
| Website | www.pulsebiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


